Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.
Abstract
Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.
참고문헌 (20)
- Smith SC Jr, "AHA", ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and American college of cardiology foundation, 2011, pp.124, 2458~2473
- Perk J, "European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)", Eur Heart J, 33, pp.1635~1701 (2012)
- Yeomans ND, "Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin", Aliment Pharmacol Ther, 22, pp.795~801 (2005)
- Sarkar M, "Proton-pump inhibitor use and the risk for community-acquired pneumonia", Ann Intern Med, 149, pp.391~398 (2008)
- Yang YX, "Long-term proton pump inhibitor therapy and risk of hip fracture", JAMA, 296, pp.2947~2953 (2006)
- Ho PM, "Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome", JAMA, 301, pp.937~944 (2009)
- Taha AS, "Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial", Lancet, 374, pp.119~125 (2009)
- Cook D, "A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian critical care trials group", N Engl J Med, 338, pp.791~797 (1998)
- Malfertheiner P, "Peptic ulcer disease", Lancet, 374, pp.1449~1461 (2009)
- Yeomans N, "Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin", Am J Gastroenterol, 103, pp.2465~2473 (2008)
- Takeuchi T, "Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin", J Gastroenterol Hepatol, 29(Suppl 4), pp.11~15 (2014)
- Naito Y, "Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study", Dig Dis Sci, 43(Suppl 9), pp.83S~89S (1998)
- Yamao J, "Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE: famotidine or rebamipide in comparison by endoscopy)", J Gastroenterol, 41, pp.1178~1185 (2006)
- Sanuki T, "Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial", J Gastroenterol, 47, pp.1186~1197 (2012)
- Sugano K, "Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study", Gut, 63, pp.1061~1068 (2014)
- Sugano K, "Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term lowdose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial", J Gastroenterol, 46, pp.724~735 (2011)
- Nakashima S, "Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin", World J Gastroenterol, 15, pp.727~731 (2009)
- Lanas A, "Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin", Aliment Pharmacol Ther, 16, pp.779~786 (2002)
- Lai KC, "Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use", N Engl J Med, 346, pp.2033~2038 (2002)
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)